

5 PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED RELEASE
 DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS

[0001] This application claims priority from U.S.
Provisional Patent Application Serial Number 60/600,907
10 which was filed on August 12, 2004.

1. Field of the Invention

[0002] This invention relates to the field of
controlled release delivery of biologically active
15 compounds and to compositions and methods useful for the
controlled release delivery of biologically active
compounds containing at least one basic group.

2. Background of the Invention

[0003] The ability to deliver biologically active
20 compounds in a controlled manner over a period of time
is an ongoing challenge. The controlled release delivery
of biologically active compounds can improve the
bioavailability by protecting them against degradation
in vivo and concomitantly replace multiple injections or
25 continuous infusions which are necessary due to the
short half-life of these biologically active compounds.
Reduced frequency for administration could improve
patient compliance. Biodegradable polymers have been
used for more than three decades as drug carriers in
30 implantable devices [*Langer, R. and Chasin, M. (Eds)*
Polymers as Drug Delivery Systems, Marcel Dekker, New
York, NY, 1990]. The advantage of using biodegradable
polymers as sustained delivery carriers for biologically
active compounds is that they do not require removal
35 after delivering their dose because they are hydrolyzed
to soluble non-toxic oligomers or monomers. The

5 biodegradation rate depends on the physicochemical
properties of the polymers, including crystallinity,
hydrophobicity, chemical structure, molecular weight and
molecular weight distribution. Theoretically, these
properties can be designed or tailored to develop drug
10 delivery systems in a controlled release manner and
desired duration of treatment.

[0004] Various biologically active compounds have
been described in the prior art in combination with
biodegradable polymers to achieve extended release by
15 using appropriate polymers under physiological
conditions. The biologically active compound in
compositions of the prior art can be in the form of an
uncharged molecule, molecular complex, salt, ether,
ester, or amide [US 6,528,080, 5,739,176, 5,077,049 and
20 US 4,938,763]. Specific examples of salts used in
injectable or implantable compositions include acetate,
chloride, citrate, maleate, phosphate, succinate,
sulfate, tartrate, etc. However, the success of such
formulations is limited to a few biologically active
25 compounds which are stable and have a wide therapeutic
blood concentration range, e.g., leuprolide, gosorelin
and rhGH. If a biologically active compound contains
reactive functional groups and has a narrow therapeutic
blood concentration window, the successful development
30 of controlled release delivery systems for such a
biologically active compound has been very challenging.
This is primarily due to the instability of the
biologically active compounds in the delivery systems
and uncontrolled release pattern of the biologically
35 active compounds from the delivery systems, e.g., burst
effect at the beginning, in the middle, and at the end

5 of the release. Some biologically active compounds
contain basic groups (including primary, secondary, and
tertiary amines) may pose serious obstacles for
successful development of controlled release delivery
systems using biodegradable polymers. The compounds may
10 alter (or catalyze) the hydrolysis process of the
polymer carrier in an uncontrolled manner and/or react
with the polymers or their degradation products to form
undesired amide drug derivatives. The formation of these
derivatives not only decreases the dose actually
15 delivered, but also may causes unexpected side effect.
The interaction/reaction between biologically active
compound and polymer carriers may occur either 1) during
formulation when the biologically active compounds are
incorporated in the polymer carrier, such as
20 microencapsulation, injection molding, extrusion
molding, mixing with polymer solutions in organic
solvent, etc.; 2) during storage and 3) during the
process of biodegradation and the release of
biologically active compounds *in vivo*.

25 [0005] The interaction/reaction between biologically
active compounds contain basic functional groups, *i.e.*,
amines, and polymers were reported during the
microparticle formation process using solvent
evaporation/extraction methods where the biologically
30 active compound and polymer were dissolved/dispersed in
organic solvents [Krishnan M. and Flanagan DR., *J*
Control Release. 2000 Nov 3;69(2):273-81]. Significant
amount of amide moieties were formed. It was clearly
shown that commonly used solvents for fabrication of
35 biodegradable polymer drug delivery systems could permit
rapid reaction between biologically active compound and

5 polymer. In another study, the accelerated degradation
of polymers by organic amines was reported [Lin WJ,
Flanagan DR, Linhardt RJ. *Pharm Res.* 1994
Jul;11(7):1030-4.]. It was also reported that the
degradation of polymer matrix containing simple drug
10 salts, e.g., epirubicin HCl, was found to hasten the
degradation of the polymers and subsequently affect the
release behavior from these particles [Birnbbaum DT,
Brannon-Peppas L. *Molecular weight distribution changes
during degradation and release of PLGA nanoparticles*
15 *containing epirubicin HCl. J Biomater Sci Polym Ed.*
2003;14(1):87-102]. Domb et al reported the drugs
containing reactive amines and their salts in the in
vitro aqueous degradation media also expedites the
degradation of biodegradable polymers [Domb AJ, Turovsky
20 L, Nudelman R., *Pharm Res.* 1994 Jun;11(6):865-8]. Both
of the reaction and catalyzed degradation are
undesirable for the controlled release delivery of
biologically active compounds for a prolonged time
period.

25 [0006] When biodegradable polymers such as
polylactic acid, polyglycolic acid, polyhydroxybutyric
acid, polyortho-esters, polyacetals and the like are
used as drug delivery systems, the biodegradation of
polymers (such as polylactide and polylactide-co-
30 glycolide for example) leads to water-uptake and
generation of aqueous channels or pores from which
biologically active compounds can leak out (or diffuse
out) if they become water soluble. In addition, the
accumulation of polymer degradation products lowers pH
35 within the degrading polymer matrices and local pH
values between 1.5 and 4.7 have been recently reported

- 5 (Na DH, Youn YS, Lee SD, Son MO, Kim WA, DeLuca PP, Lee
KC. *Monitoring of peptide acylation inside degrading
PLGA microspheres by capillary electrophoresis and
MALDI-TOF mass spectrometry. J Control Release. 2003 Oct*
10 *30;92(3):291-9; and references cited therein*). The
acidic microenvironment inside the polymer matrices can
induce several undesired chemical degradation reactions,
especially for the biologically active compounds
containing reactive amine groups, such as peptides and
proteins.
- 15 [0007] More examples with respect to the instability
or reaction/interaction of biologically active compounds
and polymers during formulation, storage, and *in vivo*
release in the prior art have been reviewed in the
literature, [Schwendeman SP., *Recent advances in the*
20 *stabilization of proteins encapsulated in injectable*
PLGA delivery systems. Crit Rev Ther Drug Carrier Syst.
2002;19(1):73-98; Sinha VR, Trehan A., Biodegradable .
microspheres for protein delivery. J Control Release.
2003 Jul 31;90(3):261-80], which are all incorporated
25 *herein by reference.*
- [0008] Some organic acids, such as acetic acid,
citric acid, benzoic acid, succinic acid, tartaric acid,
heparin, ascorbic acid and their non-toxic salts, have
been described in the prior art and used in various
30 controlled release biodegradable systems as polymer
degradation enhancers. (PCT-patent application
WO93/17668 (page 14, lines 4-13) and US patent
4,675,189) (Column 11, lines 5-19). Thus, such acid
additives are not expected to stabilize the polymers.
- 35 [0009] Various other approaches have been
investigated to achieve successful controlled release

5 delivery of biologically active compounds containing
reactive basic groups. However, despite tremendous
research efforts, there are only a few products for
controlled release delivery of biologically active
compounds commercially available so far [see e.g., US
10 Pat. Nos. 4,728,721 (Leuprolide, Lupron Depot);
4,938,763 (Leuprolide, Eligard); 5,225,205 (Triptorelin
Pamoate, Trelstar); 4,767,628 (Goserelin Acetate,
Zoladex); 5,538,739 (Octreotide, SANDOSTATIN LAR);
5,654,010 (recombinant human growth hormone, Nutropin
15 Depot); 4,675,189; 5,480,656; 4,728,721].

[0010] Clearly, there is a need to develop novel and
suitable delivery system which stabilizes the
biologically active compounds, controls the degradation
of polymers, limits the burst effect, and maintains drug
20 release within therapeutic limits for the duration of
the treatment. Thus, it is an object of this invention
to address the above-enumerated deficiencies in the
prior art and provide a pharmaceutical composition for
controlled release delivery of biologically active
25 compounds to a subject comprising:

- a) a complex of a biologically active compound
having at least one basic functional group and a
polyanion derived from hexahydroxycyclohexane
having at least two negatively charged functional
30 groups; and
- b) a pharmaceutically acceptable carrier comprising
a biodegradable, water-insoluble polymer.

[0011] The instant invention also provides methods
for producing such controlled release pharmaceutical
35 compositions and methods of use thereof.

5

SUMMARY OF THE INVENTION

[0012] The present invention provides compositions and methods for the controlled release delivery of one or more biologically active compounds to a subject. Specifically, a pharmaceutical composition for
10 controlled release delivery of biologically active compounds to a subject comprising: a) a complex of a biologically active compound having at least one basic functional group and a polyanion derived from hexahydroxycyclohexane having at least two negatively
15 charged functional groups; and b) a pharmaceutically acceptable carrier comprising a biodegradable, water-insoluble polymer. . By complexing a biologically active compound with a polyanion, the tight, stable complex may be incorporated into a long-acting dosage system having
20 a low initial burst release and a more desired drug release curve over time than that is found in much of the prior art.

[0013] It is surprisingly found that the polyanions of the invention may reduce or prevent the
25 interaction/reaction between biologically active compounds containing basic groups and polymers or their degradation products by forming stable complexes. The complexes may have low solubility in water or biological fluid. Preferably the complexes also have low solubility
30 in the solvents used to prepare the dosage form. These properties can not only stabilize the biologically active compound and slow the degradation of polymer during the formulation process, but also during release by reducing or preventing the interaction/reaction
35 between the biologically active compound and the polymer and/or its degradation products. More importantly, these

5 properties may result in the delivery of biologically
active compounds from biodegradable polymer carriers
with a highly desirable release profile. It can permit
continuous delivery of a biologically active compound to
a subject for prolonged periods of time, e.g., from
10 weeks to months to benefit the subject.

[0014] It is therefore an object of this invention
to provide a pharmaceutical composition for controlled
release delivery of biologically active compounds to a
subject comprising: a) a complex of a biologically
15 active compound having at least one basic functional
group and a polyanion derived from
hexahydroxycyclohexane having at least two negatively
charged functional groups; and b) a pharmaceutically
acceptable carrier comprising a biodegradable, water-
20 insoluble polymer..

[0015] It is a further object of the present
invention to provide a group of biologically active
compounds containing at least one basic functional group
that could benefit from the sustained controlled release
25 delivery systems.

[0016] It is a further object of the present
invention to provide a group of polyanions that can form
stable complex with biologically active compounds.

[0017] It is a further object of the present
30 invention to provide a process for making the complexes
between a biologically active compound and a polyanion
of the invention.

[0018] It is a further object of the present
invention to provide a complex which may reduce or
35 prevent the undesired degradation of polymers by the
biologically active compound not only during the

5 formulation and storage, but also during the degradation of polymer and drug release *in vivo*.

[0019] It is a further object of the present invention to provide a complex which may stabilize the biologically active compound not only during formulation
10 and storage, but also during the degradation of polymer and drug release *in vivo*.

[0020] It is a further object of the present invention to provide a pharmaceutically acceptable carrier comprising biodegradable water insoluble
15 polymers having dispersed therein the biologically active compound/polyanion complex that exhibits sustained release of the biologically active compound.

[0021] It is a further object of the present invention to provide a pharmaceutically acceptable
20 composition having incorporated therein the biologically active compound/polyanion complex that can release the biologically active compound which has retained their biological activities.

[0022] It is a further object of the present
25 invention to provide a pharmaceutically acceptable composition for use in medical applications, such as drug delivery, vaccination, gene therapy, etc.

[0023] It is a further object of the present invention to provide a pharmaceutically acceptable
30 composition suitable for oral or parenteral administrations; mucosal administration; ophthalmic administration; subcutaneous, intraarticular, or intramuscular injection; administrations by inhalation; and topical administrations.

35 [0024] These and other objects of the present invention will become apparent after reading the

5 following detailed description of the disclosed
embodiments.

DETAILED DESCRIPTION OF THE INVENTION

[0025] The present invention relates to pharmaceutical
10 compositions for the controlled release delivery of
biologically active compounds to a subject comprising:
a) a complex of a biologically active compound having at
least one basic functional group and a polyanion derived
from hexahydroxycyclohexane having at least two
15 negatively charged functional groups; and b) a
pharmaceutically acceptable carrier comprising a
biodegradable, water-insoluble polymer, and methods of
making and using such compositions. The compositions of
the invention can be prepared in any conventional
20 pharmaceutical administration forms by the method known
in the art. Non-limiting examples of the compositions of
the invention are solutions, suspensions, dispersions,
emulsions, drops, aerosols, creams, semisolids, pastes,
capsules, tablets, solid implants, or microparticles.
25 The advantages of the pharmaceutical compositions of the
invention include low initial burst and stable
controlled release of biologically active compounds *in*
vivo. It can permit continuous delivery of a
biologically active compound to a subject for prolonged
30 periods of time, e.g., from days to months.

[0026] The terms "a", "an" and "one", as used
herein, are meant to be interpreted as "one or more" and
"at least one."

[0027] The term "biologically active compound" is
35 meant to include any materials having diagnostic and/or
therapeutic properties including, but not limited to,

5 small molecules, macromolecules, peptides, proteins, or enzymes. Non-limiting examples of therapeutic properties are antimetabolic, antifungal, anti-inflammatory, antitumoral, antiinfectious, antibiotics, nutrient, agonist, and antagonist properties.

10 [0028] More specifically, the biologically active compounds of the invention may be any compounds capable of forming a complex with a polyanion derived from hexahydrocyclohexane, in particular a compound containing an electron donor base group such as a basic

15 nitrogen atom, e.g. an amine, imine or ring nitrogen. The biologically active compounds preferably contain one or more exposed protonatable amine functionalities, particularly preferably a plurality of such groups. Biologically active compounds useful in the preparation

20 of the stable complex of the invention include, but are not limited to, doxorubicin, doxycyclin, diltiazam, cyclobenzaprine, bacitracin, noscapine, erythromycin, polymyxin, vancomycin, nortriptyline, quinidine, ergotamine, benztropine, verapamil, flunarizine,

25 imipramine, gentamycin, kanamycin, neomycin, amoxicillin, amikacin, arbekacin, bambermycins, butirosin, dibekacin, dihydrostreptomycin, fortimicin, isepamicin, micronimicin, netilmicin, paromycin, ribostamycin, rapamycin, sisomicin, streptomycin and

30 tobramycin, amikacin, neomycin, streptomycin and tobramycin, pyrimethamine, naltrexone, lidocaine, prilocaine, mepivacaine, bupivacaine, tetracaine, ropivacaine, oxytocin, vasopressin, adrenocorticotrophic hormone (ACTH), epidermal growth factor (EGF), platelet-

35 derived growth factor (PDGF), prolactin, luteinising hormone, luteinizing hormone releasing hormone (LHRH),

5 LHRH agonists, LHRH antagonists, growth hormones
 (including human, porcine, and bovine), growth hormone
 releasing factor, insulin, erythropoietin (including all
 proteins with erythropoietic activity), somatostatin,
 glucagon, interleukin, interferon-.alpha., interferon-
 10 .beta., interferon-.gamma., gastrin, tetragastrin,
 pentagastrin, urogastrone, secretin, calcitonin,
 enkephalins, endorphins, angiotensins, thyrotropin
 releasing hormone (TRH), tumor necrosis factor (TNF),
 parathyroid hormone (PTH), nerve growth factor (NGF),
 15 granulocyte-colony stimulating factor (G-CSF),
 granulocyte macrophage-colony stimulating factor (GM-
 CSF), macrophage-colony stimulating factor (M-CSF),
 heparinase, vascular endothelial growth factor (VEG-F),
 bone morphogenic protein (BMP), hANP, glucagon-like
 20 peptide (GLP-1), exenatide, peptide YY (PYY), renin,
 bradykinin, bacitracins, polymyxins, colistins,
 tyrocidine, gramicidins, cyclosporins (which includes
 synthetic analogues and pharmacologically active
 fragments thereof), enzymes, cytokines, antibodies,
 25 vaccines, antibiotics, antibodies, glycoproteins,
 follicle stimulating hormone, kyotorphin, taftsin,
 thymopoietin, thymosin, thymostimulin, thymic humoral
 factor, serum thymic factor, colony stimulating factors,
 motilin, bombesin, dinorphin, neurotensin, cerulein,
 30 urokinase, kallikrein, substance P analogues and
 antagonists, angiotensin II, blood coagulation factor
 VII and IX, lysozyme, gramicidines, melanocyte
 stimulating hormone, thyroid hormone releasing hormone,
 thyroid stimulating hormone, pancreozymin,
 35 cholecystokinin, human placental lactogen, human
 chorionic gonadotrophin, protein synthesis stimulating

5 peptide, gastric inhibitory peptide, vasoactive
intestinal peptide, platelet derived growth factor, and
synthetic analogues and modifications and
pharmacologically-active fragments thereof.

[0029] The term "polyanion", as defined herein, is
10 meant to include any molecules containing at least two
or more negatively charged functional groups. Polyanions
of the invention are derived from hexahydroxycyclohexane
by esterifying with phosphate or sulfate groups capable
of forming stable complexes with the biologically active
15 compounds. Myo-inositol is one of nine known cis-trans
isomers of hexahydroxycyclohexane, a 6-carbon ring
structure found in abundance in plants and animals. For
example, inositol hexaphosphate (InP6, phytic acid) is a
natural dietary ingredient and constitutes 0.4-6.4%
20 (w/w) of most cereals, legumes, nuts, oil seeds and
soybean. An expanding body of evidence indicates that
many, if not all, mammalian cells contain inositol
polyphosphates with 5 or more phosphate groups. For
example, InP6 is found in most mammalian cells, where it
25 may assist in regulating a variety of important cellular
functions. InP6 has also been shown to function as an
antioxidant by chelating divalent cations such as copper
and iron, preventing the generation of reactive oxygen
species responsible for cell injury and carcinogenesis.
30 Some other examples of inositol polyanion include, but
not limited to, lower inositol phosphates, (i.e.,
inositol pentaphosphate, inositol tetraphosphate,
inositol triphosphate, inositol diphosphate), and other
polyphosphorylated organic compounds, inositol
35 hexasulphate (InS6) and lower inositol sulfates. The
polyanions can be either in acid or in salt forms.

5 [0030] The polyanions of at least two or more negatively charged groups are especially preferred, in particular, the inositol hexaphosphate (InP6, phytic acid), and inositol hexasulphate (InS6).

[0031] The term "stable complex" is meant to refer
10 to a physically and chemically stable complex that forms upon appropriate combining of a biologically active compound and polyanion under conditions such that a stable complex is formed, e.g., aqueous solutions of the biologically active compound and polyanion are mixed
15 until the complex forms. The complex may be in the form of a solid (e.g., a paste, granules, a powder or a lyophilizate) or the powdered form of the complex can be pulverized finely enough to be homogeneously dispersed in biodegradable polymer carriers. This complex
20 typically takes the form of a precipitate that is produced upon combining aqueous preparations of the biologically active compound and polyanion. Optionally, one or more pharmaceutically acceptable excipients may be incorporated into the complex. Such excipients may
25 function as stabilizers for the biologically active compound or its complex. Non-limiting examples include sodium bisulfite, *p*-aminobenzoic acid, thiourea, glycine, methionine, mannitol, sucrose, polyethylene glycol (PEG), and the like.

30 [0032] By way of example, a soluble antibiotics (e.g. doxorubicin) may be dissolved in water and a solution of InP6 may be added thereto. The drug:InP6 complex precipitates out. The precipitates can be washed and then separated by centrifugation or filtration. The
35 separated complex was dried under vacuum.

5 [0033] As a further example, to a solution of a local anesthetic (e.g. tetracaine hydrochloride) there may be added an aqueous solution of InP6. The drug:InP6 complex precipitates out.

[0034] As a further example, to a solution of a
10 peptide (e.g. glycagon like peptide 1 (GLP-1)) there may be added an aqueous solution of InP6. The peptide:InP6 complex precipitates out. The precipitates can be washed and then separated by centrifugation or filtration. The separated complex was dried under vacuum.

15 [0035] As a further example, to a solution of an enzyme (e.g. lysozyme) there may be added an aqueous solution of InP6. The enzyme:InP6 complex precipitates out. The precipitates can be washed and then separated by centrifugation or filtration. The separated complex
20 was dried under vacuum.

[0036] The stable complex between a biologically active compound and polyanion of the invention can be incorporated into a pharmaceutically acceptable carrier comprising biodegradable water-insoluble polymers,
25 optionally with some excipients. The term "biodegradable water-insoluble polymer" is meant to include any biocompatible and/or biodegradable synthetic and natural polymers that can be used *in vivo*. The "biodegradable water-insoluble polymer" is also meant to include the
30 polymers that are insoluble or become insoluble in water or biological fluid at 37 °C. The polymers may be purified, optionally, to remove monomers and oligomers using techniques known in the art (e.g, US Patent 4,728,721). Some non-limiting examples of the polymers
35 are polylactides, polyglycolides, poly(lactide-co-glycolide)s, polycaprolactones, polydioxanones,

5 polycarbonates, polyhydroxybutyrates, polyalkylene
oxalates, polyanhydrides, polyamides, polyesteramides,
polyurethanes, polyacetals, polyorthocarbonates,
polyphosphazenes, polyhydroxyvalerates, polyalkylene
succinates, and polyorthoesters, and copolymers, block
10 copolymers, branched copolymers, terpolymers and
combinations and mixtures thereof.

[0037] Further, the biodegradable water-insoluble
polymer can include end capped, end uncapped, or a blend
of end capped, end uncapped polymers. An end capped
15 polymer is generally defined as having capped carboxyl
end groups. An uncapped polymer is as classically
defined in the art, specifically having free carboxyl
end groups.

[0038] Suitable molecular weights for polymers may be
20 determined by a person of ordinary skill in the art.
Factors that may be considered when determining
molecular weights include desired polymer degradation
rate, mechanical strength, and rate of dissolution of
polymer in solvent. Typically, a suitable range of
25 molecular weights of polymers is of about 2,000 Daltons
to about 150,000 Daltons with a polydispersity of from
1.1 to 2.8, depending upon which polymer is selected for
use, among other factors.

[0039] As used herein, the term of "pharmaceutically
30 acceptable carrier" is intended to include any carriers
with environment responsive properties (e.g.,
thermosensitive, pH sensitive, electrical sensitive,
etc.), injectable solutions or suspensions, particles,
films, pellets, cylinders, discs, microcapsules,
35 microspheres, nanospheres, microparticles, wafers,

5 micelles, liposomes, and other known polymeric configurations used for drug delivery.

[0040] Methods for forming various pharmaceutically acceptable polymer carriers are well known in the art. For examples, various methods and materials are
10 described in US Patents: 6,410,044; 5,698,213; 6,312,679; 5,410,016; 5,529,914; 5,501,863; and PCT Publication No. WO 93/16687; 4,938,763; 5,278,201; 5,278,202; EP 0,058,481; which are all incorporated herein by reference.

15 [0041] According to the invention, compositions can be produced when biologically active compound/polyanion complex are dispersed in polymeric matrix to form solid implants, which can be injected or implanted to a subject. These implants can be prepared from the
20 biologically active compound/polyanion complex of the invention, optionally containing pharmaceutically acceptable excipients, using conventional polymer melt-processing techniques, such as, but not limited to, extrusion, compression and injection molding, wherein
25 elevated temperatures (preferably less than 100 °C) are used to melt the polymer matrix in the preparation of the implant. Preparations of such implants can be carried out under aseptic conditions, or alternatively by terminal sterilization by irradiation, using but not
30 limited to, Gamma irradiation or electron beam sterilization.

[0042] According to one embodiment of the present invention, homogeneous mixture of biologically active compound/polyanion complexes and polymers can be
35 prepared by dry-mixing in any appropriate apparatus, for example in a ball mill, and at room temperature or even

5 at a lower temperature, for example $<10^{\circ}\text{C}$. The
proportion of the powdered components can vary within a
broad range, for example from 0.1 to 30% in weight for
the biologically active compound, depending upon the
therapeutic effects required. Homogeneous mixture of
10 biologically active compound/polyanion complexes and
polymers can also be prepared by dispersing the
complexes in polymer solution in an organic solvent,
followed by the removal of the organic solvent by
evaporation or lyophilization. The resulting solid can
15 be pulverized to fine powders.

[0043] According to the invention, once a given
mixture is well homogenized, it can be molded using the
techniques known in the art. For example, it can be
progressively compressed with progressive heating
20 before being molded. The compression ratio may vary
depending on numerous factors, such as the geometry of
the apparatus or the grain size of the powdered mixture.
The control of the preheating and of the change it
undergoes as the mixture progresses is more critical:
25 depending upon the nature of the products to be treated
(copolymer, biologically active compound), every
endeavor is made to maintain a temperature gradient not
exceeding approximately 100°C . The initial temperature
to which the powdered mixture is subjected can be 25°C ,
30 lower or higher, depending on circumstances.

[0044] The molding temperature should be kept as low
as possible, preferably, not exceed 100°C , and the upper
limit of the temperature is dictated by the nature of
the biologically active compound, which should not
35 undergo deterioration. An adequate pressure and an
adequate temperature promote the perfect homogenization

5 of the ingredients and, in particular, the uniform distribution of the complex throughout the mass of the copolymer can be readily determined by simple experimentations.

[0045] Alternatively, the homogenized powders can be
10 compression molded at room temperature, similar to the preparation of FTIR pellet.

[0046] In one embodiment of the invention, a copolymer of D,L-lactide and glycolide with a 50/50 molar ratio of D,L-lactide to glycolide is dissolved in
15 methylene chloride. To this solution, tetracaine phytate is added and dispersed with a high shear mixer. The resulting mixture is placed in a rotating evaporator and the majority of the methylene chloride is removed under vacuum. The resulting thick dispersion is poured onto a
20 glass plate to form a film. The film thus obtained is melted and compression molded to give a film about 0.5 mm thick.

[0047] According to the invention, alternatively, the homogenized powders can be melted and compression
25 extruded or injection molded into different shapes of solid implants as known in the art. The actual extrusion can be carried out by means of a nozzle of standard shape and dimensions. The cooling of the extruded product is achieved by any appropriate means, such as
30 cold sterile air or gas or simply through natural loss of heat.

[0048] According to the invention, these solid dosage forms, e.g., fiber, rod, film, or wafer, can be reduced to microparticulate forms by comminution or milling. The
35 extruded or molded product described above adequately cooled is then pulverized at low temperature, preferably

5 at a temperature lower than 0 °C, or even much lower, for
example -20 °C. The product thus pulverized may then be
subjected to sieving to obtain desired particle size.
The preferred particle sizes may range from 1 μ m to 500
10 μ m, and these microparticle delivery systems can be
suspended in a suitable conventional pharmaceutically
acceptable injection vehicle.

[0049] According to another aspect of the invention,
particularly effective and useful parenteral
pharmaceutical formulations of biologically active
15 compounds can also be prepared in the form of solutions
or suspensions of a polymer in a pharmaceutically
acceptable solvent containing dispersed or solubilized
drug/polyanion complex . By complexation with a
polyanion, the reactive groups in biologically active
20 compound are not available to interact with polymer in
solution. Thus, the stability of biologically active
compound in the compositions of the present invention
was improved by complexing with polyanions of the
invention.

25 [0050] Thus, according to the present invention,
however, there is provided a pharmaceutical composition
comprising a biologically active compound complexed with
a polyanion and a polymer, for extended release of the
biologically active compound, characterized in that the
30 composition is in the form of an injectable
solution/suspension, comprising:

- (a) a complex of a biologically active compound
having at least one basic functional group and a
derivative of hexahydroxycyclohexane having at
35 least two negatively charged functional groups; and
- (b) a biodegradable water-insoluble polymer;

5 (c) a pharmaceutically acceptable organic solvent
which is a solvent for the polymer

[0051] Suitable biologically active compound and
polyanion are those defined above, and particularly
preferred polyanions are those containing at least two
10 phosphate or sulfate groups as defined above, more
preferably InP6 or InS6.

[0052] The molar ratio of biologically active
compound to polyanion in the complex will vary from
0.1:1 to 1:0.1 according to the nature of biologically
15 active compound and polyanion, and the period of peptide
drug release desired.

[0053] Any suitable biodegradable polymer can be
employed, provided the polymer is insoluble or become
insoluble in aqueous medium or body fluid at 37 °C.
20 Suitable biodegradable polymers are those defined above.

[0054] The type, molecular weight, and amount of
biodegradable polymer present in the compositions can
influence the length of time in which the biologically
active compound is released from the controlled release
25 implant. The selection of the type, molecular weight,
and amount of biodegradable polymer present in the
compositions to achieve desired properties of the
controlled release implant can be performed by a person
with ordinary skills in the art.

30 [0055] Suitable pharmaceutically acceptable organic
solvent include, but not limited to, N-methyl-2-
pyrrolidone, N, N-dimethylformamide, dimethyl sulfoxide,
propylene carbonate, caprolactam, triacetin, benzyl
benzoate, benzyl alcohol, ethyl lactate, glyceryl
35 triacetate, esters of citric acid, and polyethylene

5 glycols, alkoxypolyethylene glycols and polyethylene glycol acetates, etc., or any combination thereof.

[0056] The criteria for the organic solvents of biodegradable polymers are that they are pharmaceutically acceptable and miscible to dispersible
10 in aqueous medium or body fluid. The suitable organic solvent should be able to diffuse into body fluid so that the liquid composition coagulates or solidifies to form an implant in place. Single and/or mixture of such solvents can be employed, the suitability of such
15 solvents can be determined readily by simple experimentations.

[0057] The pharmaceutical compositions of the invention typically contain biologically active compound in a range of 0.1 to 40% w/v. In general, the optimal
20 drug loading is dependent upon the period of release desired and the potency of the biologically active compound. Obviously, for biologically active compound of low potency and longer period of release, higher levels of incorporation may be required.

25 [0058] The viscosity of the solution compositions of the invention is determined by the molecular weight of the polymer and organic solvent used. For example, when poly(lactide-co-glycolide) is used, the solution of polyester in NMP has a lower viscosity than in mPEG350.
30 Typically, when the same solvent is used, the higher the molecular weight and concentration of the polymer, the higher the viscosity. Preferably the concentration of the polymer in solutions is below 70% by weight. More preferably concentration of the polymer in solutions is
35 between 20 to 50% by weight.

5 [0059] Preferably, the complex should have a low solubility in organic solvent used. The reactive groups of the biologically active compound will be bound to the polyanion and thus are not available for interaction/reaction with polymer or solvent. This
10 greatly reduces the risk of unfavorable interaction/reaction with the polymer and its degradation products.

[0060] According to one embodiment of the present invention, a simple salt, tetracaine chloride, is mixed
15 with 50/50 poly(DL-lactide-co-glycolide) having a carboxy terminal group solution in NMP. For the *in vitro* studies, small drops of the mixture (about 100 mg) are added to phosphate buffered saline solution. The receiving fluid is replaced at selected time points with
20 fresh solution, and the removed PBS solution is analyzed for drug concentration using appropriate analytical methods.

[0061] According to another embodiment of the present invention, tetracaine phytate is mixed with 50/50
25 poly(DL-lactide-co-glycolide) having a carboxy terminal group solution in NMP. The drug complex was dispersed uniformly in the polymer solution. For the *in vitro* studies, small drops of the mixture (about 100 mg) are added to phosphate buffered saline solution. The
30 receiving fluid is replaced at predefined time points with fresh solution, and the removed PBS solution is analyzed for drug concentration using appropriate analytical methods.

[0062] According to another embodiment of the present
35 invention, octreotide phytate and octreotide acetate were mixed with 50/50 poly(DL-lactide-co-glycolide) having a

5 carboxy terminal group solution in NMP and methoxypolyethylene glycol 350. The drug complex was dispersed uniformly in the polymer solutions. The compositions were kept at room temperature and the stability of octreotide in the composition was monitored
10 by HPLC analysis over time. The complexation of octreotide with phytic acid significantly improved the stability of octreotide in the composition over time.

[0063] According to another embodiment of the present invention, octreotide phytate and octreotide acetate were
15 mixed with 50/50 poly(DL-lactide-co-glycolide) having a carboxy terminal group solution in NMP and methoxypolyethylene glycol 350. The drug complex was dispersed uniformly in the polymer solutions. The compositions were administered subcutaneously in
20 Sprague-Dawley male rats to form an implant in place. The initial release of octreotide was determined by implant retrieval at predefined time intervals after administration and analysis of the octreotide remaining in the implant. The stability of octreotide during the
25 formulation and release was also evaluated. The complexation of octreotide with phytic acid significantly lowered the initial release of octreotide and improved the stability of octreotide during the release process over time.

30 [0064] The release of biologically active compound from these implants formed in place will follow the same general rules for release of a drug from a monolithic polymeric device. The release of biologically active compound can be affected by the size and shape of the
35 implant, the loading of biologically active compound within the implant, the permeability factors involving

5 the biologically active compound and the particular
polymer, and the degradation of the polymer. Depending
upon the amount of biologically active compound selected
for delivery, the above parameters can be adjusted by
one skilled in the art of drug delivery to give the
10 desired rate and duration of release.

[0065] The amount of injectable solution composition
administered will typically depend upon the desired
properties of the controlled release implant. For
example, the amount of injectable solution composition
15 can influence the length of time in which the
biologically active compound is released from the
controlled release implant.

[0066] According to another aspect of the invention,
compositions in the forms of microspheres are produced
20 by encapsulating biologically active compound/polyanion
complex in polymeric carrier. The biologically active
compound/polyanion complex can be encapsulated using
various biocompatible and/or biodegradable polymers
having unique properties which are suitable for delivery
25 to different biological environments or for effecting
specific functions. The rate of dissolution and,
therefore, delivery of biologically active compound is
determined by the particular encapsulation technique,
polymer composition, polymer crosslinking, polymer
30 thickness, polymer solubility, size and solubility of
biologically active compound/polyanion complex.

[0067] Biologically active compound/polyanion complex
to be encapsulated are suspended in a polymer solution
in an organic solvent. The polymer solution must be
35 concentrated enough to completely coat the biologically
active compound/polyanion complex after they are added

5 to the solution. Such an amount is one which provides a weight ratio of biologically active compound/polyanion complex to polymer between about 0.01 and about 50, preferably between about 0.1 and about 30. The biologically active compound/polyanion complex should be
10 kept suspended and not allowed to aggregate as they are coated by contact with the polymer.

[0068] Preferably, the complex should have a very low solubility in organic solvent used. The reactive groups of the biologically active compound will be bound to the
15 polyanion and thus are not available for interaction with polymer or solvent. This greatly reduces the risk of unfavorable interaction with the polymer.

[0069] A polymer solution of the biologically active compound/polyanion complex can therefore be subjected to
20 a variety of microencapsulation techniques including spray drying, spray congealing, emulsion, solvent evaporation emulsion.

[0070] According to one embodiment of the invention, the biologically active compound/polyanion complex is
25 suspended in a polymer solution in an organic solvent. The suspended complexes or microparticles along with the polymer and organic solvent are transferred to a larger volume of an aqueous solution containing an emulsifier. In the aqueous solution, the suspended complexes are
30 immersed in the aqueous phase, where the organic solvent evaporates or diffuses away from the polymer. The solidified polymer encapsulates the biologically active compound/polyanion complex to form a composition. The emulsifier helps to reduce the interfacial surface
35 tension between the various phases of matter in the system during the hardening phase of the process.

5 Alternatively, if the encapsulating polymer has some inherent surface activity, there may be no need for addition of a separate surface active agent.

[0071] Emulsifiers useful to prepare encapsulated biologically active compound/polyanion complex according
10 to this invention include poloxamers and polyvinyl alcohol as exemplified herein, surfactants and other surface active compounds which can reduce the surface tension between the polymer encapsulated biologically active compound/polyanion complex and the solution.

15 [0072] Organic solvents useful to prepare the microspheres of the present invention include acetic acid, acetone, methylene chloride, ethyl acetate, chloroform and other non-toxic solvents which will depend on the properties of the polymer. Solvents should
20 be chosen that solubilize the polymer and are ultimately non-toxic.

[0073] A preferred embodiment of this invention is that the integrity of the biologically active compound/polyanion complex is maintained during the
25 encapsulation process. The complexation is maintained during the suspending process by using an organic solvent in which the biologically active compound/polyanion complex has a very low solubility. Subsequently, once the coated complexes are transferred
30 to the aqueous solvent, rapid hardening of the polymeric carrier and sufficient encapsulation of the biologically active compound/polyanion complex in the previous step shields the complex material from dissolution.

[0074] The polymers used to encapsulate the
35 biologically active compound/polyanion complex can be either homo-polymers or co-polymers as described above.

5 [0075] In another embodiment, double-walled polymer coated microspheres may be advantageous. Double-walled polymer coated microspheres may be produced by preparing two separate polymer solutions in methylene chloride or other solvent which can dissolve the polymers. [See
10 *Pekarek, K. J.; Jacob, J. S. and Mathiowitz, E. Double-walled polymer microspheres for controlled drug release, Nature, 1994, 367, 258-260*]. The biologically active compound/polyanion complex are added to one of the solutions and dispersed. Here, the biologically active
15 compound/polyanion complex become coated with the first polymer. Then, the solution containing the first polymer coated biologically active compound/polyanion complex is combined with the second polymer solution. Now, the second polymer encapsulates the first polymer which is
20 encapsulating the biologically active compound/polyanion complex. Ideally, this solution is then dripped into a larger volume of an aqueous solution containing a surface active agent or emulsifier. In the aqueous solution, the solvent evaporates from the two polymer
25 solutions and the polymers are precipitated to encapsulate the complex.

[0076] Although the formulations described above are primarily those for injectable or implantable routes of administration, the biologically active
30 compound/polyanion complex of the invention may also be used in the manufacture of orally, nasally, or topically administrable formulations.

[0077] Thus, according to the present invention, the compositions containing the biologically active
35 compound/polyanion complex can be administered to a subject where sustained controlled release delivery of a

5 biologically active compound is desired. As used herein, the term "subject" is intended to include warm-blooded animals, preferably mammals, most preferably humans.

[0078] As used herein, the term "administered to a subject" is intended to refer to dispensing, delivering
10 or applying a composition (e.g., pharmaceutical formulation) to a subject by any suitable route for delivery of the composition to the desired location in the subject, including delivery by oral, by nasal, by injection and/or implantation subcutaneously,
15 intramuscularly, intraperitoneally, intradermally, intravenously, intraarterially, or intrathecally, by administration to mucosal membranes, or by in situ delivery to provide the desired dosage of a biologically active compound based on the known parameters for
20 treatment of the various medical conditions with the biologically active compound.

[0079] The term "controlled release delivery", as defined herein, is intended to refer to continual delivery of a pharmaceutical agent *in vivo* over a period
25 of time following administration, preferably at least several days to weeks or months. Sustained controlled release delivery of the agent can be demonstrated by, for example, the continued therapeutic effect of the agent over time (e.g., for GLP-1, sustained delivery of the peptide can be demonstrated by continued A1c
30 reductions over time). Alternatively, sustained delivery of the agent may be demonstrated by detecting the presence of the agent *in vivo* over time.

[0080] All books, articles and patents referenced
35 herein are fully incorporated by reference.

5 **EXAMPLES**

[0081] The following examples illustrate the compositions and methods of the present invention. The following examples should not be considered as limitations, but should merely teach how to make the useful drug delivery systems.

Example 1 Preparation of doxorubicin phytate (DOX-PA)

[0082] 2 mg/mL solution of doxorubicin hydrochloride (MW 578.98) in water (3.45 mM) and 20 mg/mL phytic acid dipotassium salt (MW 736.22) in water (27.2 mM) were prepared. To 100 mL of doxorubicin hydrochloride solution, 2.1 mL of phytic acid solution was added while stirring the solution. The expected ratio of phytic acid to doxorubicin was 1:6. The mixture was centrifuged. The precipitate was washed four times with water and then lyophilized. The yield is 187 mg (88.5%).

[0083] The solubility of doxorubicin phytate was measured in deionized water, phosphate buffered saline (PBS, pH 7.4), Dimethylsulfoxide (DMSO), Dimethylacetamide (DMAC), *N*-Methyl-2-pyrrolidone (NMP), and methoxypolyethylene glycohol 350 (mPEG). Results are shown in the table below:

Solvents	Solubility (μ g/mL)
H ₂ O	4.5
PBS (pH 7.4)	11.2
DMSO	Soluble
DMAC	50
NMP	50
mPEG	0

Example 2 Preparation of Microspheres Containing DOX-PA and DOX-HCl

30

[0084] 121 mg DOX-PA complex was dispersed in the solution of PLGA (DL5050 3A, Alkermes) in methylene

5 chloride (DCM). The above organic phase was emulsified
in 500 mL of 1.0% (w/v) PVA solution which was pre-
cooled in the refrigerator (~4°C). The emulsion was
continued to stir for 3 h at RT to evaporate the DCM.
The hardened microspheres were collected by decanting
10 off the supernatant, washed three times with deionized
water, and then freeze-dried. Reddish microspheres were
obtained. The drug content in the microspheres is ~5.1%
as determined by HPLC.

[0085] The microspheres containing DOX-HCl were
15 prepared by using DOX-HCl in the place of DOX-PA using
the same procedure above.

**Example 3 - Preparation of encapsulated doxorubicin
phytate**

[0086] The doxorubicin phytate prepared in Example 1
20 is encapsulated in polylactic-co-glycolic acid (PLGA)
using a double emulsion method. 1.4 mg of doxorubicin
phytate is added in methylene chloride containing PLGA
(0.6 g PLGA/mL solvent; 20 mL). The mixture is
homogenized for 30 sec at 3,000 rpm, using a homogenizer
25 with a microfine tip. The resulting suspension is
transferred to a stirred tank (2000 mL) containing 1%
poly(vinyl alcohol) (PVA) and methylene chloride (4.5
mL). The solution is mixed at 1,000 rpm for 1 min. The
microspheres in the PVA solution are precipitated by
30 immersion in distilled water, washed and filtered. The
microspheres are then washed with distilled water
containing 0.1% Tween, to reduce agglomeration and dried
with nitrogen for 2 days at 4 °C.

Example 4 - Preparation of tetracaine phytate

35 [0087] 1.0 g tetracaine hydrochloride (3.33 mmol) was
dissolved in 40 mL water and with vigorous stirring,
20.5 mL of the phytic acid solution of Example 1 was

5 added. After another 30 min of stirring, the precipitate was centrifuged and washed with water. The final products were in the form of white powder. The solubility of the complex in different buffers is shown below.

Solvents	Solubility (mg/mL)
PBS (pH 7.4)	7.5
H ₂ O (~pH 6.0)	4.5
Acetate Buffer (pH 4.5)	2.7

10 **Example 5 - Preparation of polymer microspheres containing tetracaine**

[0088] Polymer (e.g., poly(lactide-co-glycolide) (PLGA) microspheres were prepared by an oil-in-water (O/W) single emulsion technique. PLGA was dissolved in methylene chloride (DCM). For the encapsulation of tetracaine, the drug was mixed with the PLGA solution in DCM. The mixed solution or suspension was emulsified in 500 mL of 0.5-1% (w/v) PVA (PVA, 88% hydrolyzed, average molecular weight of 31,000-50,000, Sigma-Aldrich) solution pre-cooled in the refrigerator at 4 °C. The emulsion was stirred continuously for 3 h at RT to evaporate the DCM. The hardened microspheres were collected, washed three times with deionized water, and then freeze-dried.

[0089] In the case of preparation of microspheres containing tetracaine phytate (TCPA), 210 mg of TCPA was suspended in 5 mL PLGA solution. The suspension was sonicated for 10 min. This suspension was slowly added to the continuous phase (1% PVA solution) pre-cooled at 4 °C while stirring. The emulsion was stirred continuously for 3 h at room temperature to evaporate the DCM. The hardened microspheres were collected, washed three times with deionized water, and then freeze-dried. The tetracaine load was about 3.2%.

5 [0090] Polymer microspheres containing tetracaine hydrochloride (TC-HCl) were prepared in a similar manner by replacing TCPA with TC-HCl.

Example 6 - Preparation of pellets containing tetracaine phytate

10 [0091] Implantable pellets containing tetracaine phytate was prepared by compression molding process. 249 mg PLGA powder were thoroughly mixed with 25.7 mg tetracaine phytate using a mortar and pestle. Then ~50 mg mixture were molded using a Delta Press to form a
15 pellet. The pellets containing tetracaine hydrochloride were also prepared for comparison.

Example 7 - Preparation of implants containing tetracaine phytate

[0092] 2.56 g of poly(lactide-co-glycolide) (PLGA) (RG504H, from Boehringer-Ingelheim) is dissolved in 7.73 grams of methylene chloride. To this solution, 256 mg of tetracaine phytate is added and dispersed with a high shear mixer.

[0093] The resulting mixture is placed in a rotating
25 evaporator and the majority of the methylene chloride is removed under vacuum. The resulting thick dispersion is poured onto a glass plate and spread with an adjustable blade set at 0.7 mm.

[0094] The film thus obtained is melted and
30 compression molded at 80 °C to give a film about 0.5 mm thick. The film is incubated in phosphate buffered saline (containing 0.02% sodium azide) at pH 7.4 and 37 °C, and the buffer solution is assayed periodically by UV to determine the amount of tetracaine released.

35 [0095] Similar molded implants can be manufactured using, in place of tetracaine, other biologically active compound containing at least one basic functional group.

5 **Example 8 - Injectable formulations of tetracaine phytate and its *in vitro* release**

[0096] 40% (w/v) of poly(DL-lactide-co-glycolide) (PLGA) having a carboxy terminal group solution in NMP is prepared by dissolving 160 mg of PLGA (RG503H, from
10 Boehringer-Ingelheim) in 0.4 mL NMP. 39.9 mg of tetracaine phytate is mixed with the polymer solution by syringe flushing. Small drops of the mixture (about 100 mg) are added to phosphate buffered saline solution at pH 7.4. The receiving fluid is replaced at selected time
15 points with fresh solution, and the removed PBS solution is analyzed for drug concentration using UV detection at 280 nm.

Example 9 - Preparation of the complex of lidocaine with phytic acid

20 [0097] 1.0 g lidocaine hydrochloride (3.69 mmol) is dissolved in 400 mL water and with vigorous stirring, 28.8 mL of the phytate solution of Example 1 is added. After 30 min, the pH is adjusted to 3.5 with 0.1 N HCl solution. After another 30 min of stirring, the
25 precipitate is filtered and washed 4 times with water. The final product is lyophilized.

Example 10 - Preparation of the complex of amoxicillin with phytic acid

[0098] 1.0 g amoxicillin hydrochloride (2.74 mmol) is
30 dissolved in 400 mL water and with vigorous stirring, 21.3 mL of the phytate solution of Example 1 is added. After 30 min, the pH is adjusted to 3.5 with 0.1 N HCl solution. After another 30 min of stirring, the precipitate is filtered and washed 4 times with water.
35 The final product is lyophilized.

[0099] Similar complexes may be manufactured by using, in place of amoxicillin hydrochloride, other compounds containing at least one basic group.

5 **Example 11 - Preparation of the complex of octreotide with phytic acid**

[00100] 20 mg/mL solution of octreotide was prepared by dissolving 215 mg octreotide in 10.75 mL water. 5 mL of this solution was mixed with 1.45 ml of PA solution
 10 (1%, w/v) at pH 3.12. The mixture was vortexed for 1 min and then the mixture was put on a rotator to mix for another hour. The complex was separated by centrifugation and rinsed with water once. The precipitated product was freeze dried for 48 h. The
 15 final product in the form of white powder was obtained.

Example 12 - The Stability of Octreotide in Injectable formulations

[00101] Injectable formulations of octreotide were prepared by dispersing octreotide in polymer solution in
 20 an appropriate solvent. For example, poly(DL-lactide-co-glycolide) (PLGA) having a 50/50 ratio of lactide to glycolide (PLG DL2.5A from Alkermes) was dissolved in *N*-methyl-2-pyrrolidone (NMP), or methoxypolyethylene glycohol (mPEG), or polyethylene glycohol dimethyl ether
 25 (PEGDM) to give a 40% solution by weight. The injectable formulations were prepared by dispersing octreotide phytate or acetate in the polymer solutions. The mixture was thoroughly mixed until a uniform suspension or solution was obtained. Six injectable formulations
 30 were prepared as shown below.

Polymer Solutions	Targeted Loading	Salt Form	Drug (mg)	PLGA/Sol. (mg)
40% 5050DL2.5A/60% NMP	50 mg/ml	Acetate	20	455
40% 5050DL2.5A/60% NMP	50 mg/ml	Phytate	20	445
40% 5050DL2.5A/60% mPEG	50 mg/ml	Acetate	20	450
40% 5050DL2.5A/60% mPEG	50 mg/ml	Phytate	20	430

40% 5050DL2.5A/60% PEGDM 50 mg/ml Aceta	20	445
te		
40% 5050DL2.5A/60% PEGDM 50 mg/ml Phyta	20	440
te		

- 5 **Note:** mPEG: Methoxy polyethyleneglycol 350; NMP: N-methyl Pyrrolidinone;
PEGDM: polyethylene glycohol dimethyl ether

[00102] The stability of octreotide in the above
10 injectable formulations at room temperature was
monitored by HPLC and the results are shown in the table
below. The complexation of octreotide with phytic acid
completely prevented the degradation and/or acylation of
octreotide in PLGA solutions in mPEG and PEGDM, while a
15 slight degradation of octreotide was observed in PLGA
solutions in NMP at room temperature over time. When
octreotide acetate was used, significant amount of the
octreotide was degraded or reacted after three days at
room temperature. In the case of PLGA solution in NMP,
20 almost 100% of octreotide was degraded or acylated.
Therefore, octreotide phytate would be the preferred
form to prepare stable formulations containing the
peptide.

Time (h)	% of intact octreotide					
	NMP /Ac	NMP /Pa	mPEG /Ac	mPEG /Pa	PEGDM /Ac	PEGDM /Pa
0	100.0	100.0	100.0	100.0	100.0	100.0
0.5	95.5	100.0	100.0	100.0	100.0	100.0
1	92.4	100.0	100.0	100.0	100.0	100.0
3	90.0	99.0	100.0	100.0	100.0	100.0
5	58.0	100.0	100.0	100.0	95.0	100.0
24	15.4	100.0	100.0	100.0	100.0	100.0
72	0.8	80.4	40.2	100.0	69.9	100.0
120	0.0	81.5	64.0	100.0	32.7	100.0
168	0.0	85.0	32.5	100.0	58.8	100.0
288	0.0	81.1	53.9	100.0	24.4	100.0

- 25 **Note:** mPEG: Methoxy polyethyleneglycol 350; NMP: N-methyl Pyrrolidinone; PEGDM: polyethylene glycohol dimethyl ether; /Ac: Octreotide in acetate form; /Pa: Octreotide in phytate form.

5 **Example 13 - The Stability of Octreotide in Injectable formulations**

[00103] Poly(DL-lactide-co-glycolide) (PLGA) having a 50/50 ratio of lactide to glycolide (DL2.5A from Alkermes) was dissolved in N-methyl-2-pyrrolidone (NMP),
 10 or methoxypolyethylene glycohol (mPEG) to give a 40% solution by weight. The injectable polymer solutions were prepared by dispersing octreotide phytate or acetate or citrate. The mixture was thoroughly mixed until a uniform suspension or solution was obtained.
 15 Injectable formulations were prepared as shown below.

Formulation	Targeted Loading	Salt Form	Drug (mg)	PLGA/Sol (mg)
40% 5050DL2.5A/60% NMP	50 mg/ml	Phytate	20	445
40% 5050DL2.5A/60% NMP	50 mg/ml	Acetate	20	455
40% 5050DL2.5A/60% NMP	50 mg/ml	Citrate	24	455
40% 5050DL2.5A/60% PEG350	50 mg/ml	Phytate	20	450

Note: mPEG: Methoxy polyethyleneglycol 350; NMP: N-methyl Pyrrolidinone.

20 [00104] The stability of octreotide in the above injectable formulations at room temperature was monitored by HPLC and the results are shown in the table below. It appears that both salt forms of octreotide and the solvent affect the stability of octreotide. In
 25 terms of the stability of octreotide, mPEG is preferred than NMP and phytate complex form of octreotide is preferred than acetate and citrate salt of octreotide.

Time points (h)	% of intact octreotide			
	NMP/Ac	mPEG/Ac	NMP/Ca	mPEG/Pa
0	100.0	100.0	100.0	100.0
1	79.8	100.0	94.9	100.0
5	43.7	100.0	57.7	
24	16.1	82.2	41.5	100.0
72	0.0	68.2	24.8	
168	0.0	54.5	13.5	100.0

336	0.0	37.4	0.0	100.0
504	0.0	28.5	0.0	100.0

5 **Note:** mPEG: Methoxy polyethyleneglycol 350; NMP: N-methyl Pyrrolidinone; /Ac: Octreotide in acetate form; /Ca: Octreotide in citrate form; /Pa: Octreotide in phytate form.

10 **Example 14 - Initial Release of Octreotide in vivo in Rats**

15 [00105] Poly(DL-lactide-co-glycolide) (PLGA) was dissolved in N-methyl-2-pyrrolidone (NMP), or methoxypolyethylene glycol (mPEG) to give a 40% solution by weight. The injectable formulations were prepared by dispersing octreotide phytate or acetate. The mixture was thoroughly mixed until a uniform suspension or solution was obtained. Injectable formulations prepared are shown in the table below. These formulations of octreotide (roughly about 100 uL) were administered subcutaneously in the back of the Sprague-Dawley male rats. The release of octreotide was determined by implant retrieval at predefined time intervals (30 min for group G and 24 h for groups A through F) after administration and analysis of the octreotide remaining in the implant. The stability of octreotide during the formulation and release was also evaluated.

ID#	Formulation	Drug Content (%)	Harvest Time (h)	Degradation (%)	Mean Release (%)
A	OCT/Pa in 40% 5050 DL2.5A/60% mPEG	4.36	24	0.00	10.82±7.10
B	OCT/Ac in 40% 5050 DL2.5A/60% mPEG	4.16	24	20.60±1.53	47.01±6.91 (34.47±8.51) *
C	OCT/Pa in 40% 5050 DL3A/60% mPEG	4.37	24	0.00	62.08±10.94

D	OCT/Pa in 40% 5050 DL3A/60% NMP	4.36	24	12.67±2.52	75.52±3.06
E	OCT/Pa 40% 5050 DL2.5A/60% NMP	4.35	24	10.00	63.41±5.97
F	OCT/Ac in 40% 5050 DL2.5A/60% NMP	4.26	24	28.81±3.45	28.82±5.02 (44.12±3.94) *
G	OCT/Pa in 40% 5050 DL2.5A/60% mPEG	4.60	0.5	0.00	3.29±7.73

5 **Note:** mPEG: Methoxy polyethyleneglycol 350; NMP: N-methyl Pyrrolidinone; OCT: Octreotide; OCT/Ac: Octreotide actate; OCT/Pa: Octreotide phytate. * Including degradation peaks

[00106] Formulations A and G are similar with a slight
 10 higher drug content for G, but the animals were
 harvested and implants were retrieved at different time
 points. The results appear to show the gradual release
 of octreotide over time. The octreotide released from
 the implants was about 3.29±7.73% in group G at 0.5 hour
 15 and 10.82±7.10% in group A at 24 hours post
 administration. Comparing to formulation B, the
 complexation of octreotide with phytic acid
 significantly improved both initial release and
 stability of the peptide in the formulation and release
 20 processes. The results also showed that mPEG was a
 preferred solvent over NMP in terms of octreotide
 stability. NMP seems to be a better solvent for both
 octreotide and PLGA which may promote the acylation
 reaction between octreotide and PLGA or its degradation
 25 products.

[00107] The results on octreotide stability in
 PLGA/NMP vehicle correlate to those obtained *in vitro*
 (refer to example 13 & 14). However, the
 degradation/reaction rate seemed slower *in vivo* than
 30 that *in vitro* (30% vs 85% after 24 h). This difference

5 could be explained by the fact that the implant was quickly formed after administration by dissipating solvent NMP to the surrounding tissues of the animals. The solvent dissipation would result in the increase of viscosity of the vehicle or solidification of the PLGA, leading to a slower reaction rate between octreotide and PLGA or its degradation products. However, the solvent dissipation was a slow process as significant amount of NMP (up to 35%) could still be detected in the implant 24 hours after administration. This indicates that the residual solvent may be trapped in the implant much longer than desired. Therefore, the use of biologically active compound in its more stable form is very important to develop a beneficial formulation.

Example 15 - In Vivo Release of Octreotide in Rats

20 [00108] The injectable formulations were prepared by dispersing octreotide phytate in Poly(DL-lactide-co-glycolide) (PLGA) solution in mPEG350. The mixture was thoroughly mixed until a uniform suspension was obtained. Injectable formulations prepared are shown in the table below. These formulations of octreotide (roughly about 100 uL) were administered subcutaneously in the back of the Sprague-Dawley male rats. The release of octreotide was determined by implant retrieval at predefined time intervals after administration and analysis of the octreotide remaining in the implant. The stability of octreotide during the formulation and release was also evaluated.

ID#	Formulation	Drug Content (%)	Harvest Time (h)	Mean Release (%)	Standard Deviation (%)
A	OCT/Pa in 40% 5050 DL2.5A/60% mPEG	3.9	24	11.1	1.7

B	OCT/Ac in 35% 5050 DL2.5A/65% mPEG	3.9	24	14.0	4.2
C	OCT/Pa in 50% RG752S /50% mPEG	10.8	24	0.4	2.0
D	OCT/Pa in 45% RG752S/55% mPEG	10.7	24	1.5	2.7
E	OCT/Pa 40% RG752S/60% mPEG	10.8	24	3.8	4.5

5 **Note:** mPEG: Methoxy polyethyleneglycol 350; NMP: OCT:
Octreotide; OCT/Pa: Octreotide phytate. 5050DL2.5A:
poly(lactide-co-glycolide) with 50% lactide from
Alkermes; RG752S: poly(lactide-co-glycolide) with 75%
lactide from Boehringer-Ingelheim (BI).

10

[00109] The initial release of OCT from formulations A
and B were 11.1 ± 1.7 % and 14.0 ± 4.2 % respectively, while
from formulations C, D, and E were 0.4 ± 2.0 %, 1.5 ± 2.7 %,
and 3.8 ± 4.5 % respectively. Although the difference was
15 not statistically significant, there seems a tendency
that the initial release of OCT increases with the
decrease of polymer concentration. In addition, OCT was
stable during the formulation process and *in vivo*
release in these formulations.

20 **Example 16 - Preparation of the complex of glycagon like
peptide 1 (GLP-1) with phytic acid**

[00110] 50 mg GLP-1 acetate (Mw 3297.7, 0.0152 mmol)
was dissolved in 5 mL water and with vigorous stirring,
1.01 mL of 1% phytic acid solution at pH 3.2 was added
25 (a molar ratio of GLP-1:phytate = 1:1). After another
30 min of stirring, the mixture was centrifuged. The
supernatant was decanted off and the precipitate was
rinsed twice with water and then freeze-dried. The final
product was in the form of white powder.

30 **Example 17 - Preparation of the complex of glycagon like
peptide 1 (GLP-1) with inositol hexasulfate (Ins6)**

5 [00111] 50 mg GLP-1 acetate (Mw 3297.7, 0.0152 mmol)
was dissolved in 5 mL water and with vigorous stirring,
1.35 mL of 1% potassium inositol hexasulfate (InS6)
solution at pH 1.0 was added (a molar ratio of GLP-
1:InS6 = 1:1). After another 30 min of stirring, the
10 mixture was centrifuged. The supernatant was decanted
off and the precipitate was rinsed twice with water and
then freeze-dried. The final product was in the form of
white powder.

15 **Example 18 - Preparation of the complex of PYY with
phytic acid**

[00112] 1.0 g PYY acetate (0.247 mmol) is dissolved in
100 mL water and with vigorous stirring, 11.5 mL of the
phytate solution of Example 1 is added (a molar ratio of
PYY:phytate = 1:1). After another 30 min of stirring,
20 the precipitate is filtered and washed 4 times with
water. The final product is lyophilized.

Example 19 - Preparation of lysozyme phytate

[00113] 100 mg lysozyme (7.1 μ mol) was dissolved in 40
mL water and with vigorous stirring, 3.1 μ L of the
25 phytate solution of Example 1 was added. After another
30 min of stirring, the precipitate was filtered, washed
4 times with water, and lyophilized. The final product
in the form of white powder was obtained.

[00114] Similar complexes may be manufactured by
30 using, in place of lysozyme, either naturally occurring
peptides/proteins or their synthetic analogues.

5

CLAIMS

I claim:

1. A pharmaceutical composition comprising:
 - a) a complex of a biologically active compound having at least one basic functional group and a polyanion derived
10 from hexahydroxycyclohexane having at least two negatively charged functional groups; and
 - b) a pharmaceutically acceptable carrier comprising a biodegradable, water-insoluble polymer.
- 15 2. The pharmaceutical composition of claim 1 wherein the derivative of hexahydroxycyclohexane has at least two phosphate groups.
3. The pharmaceutical composition of claim 1 wherein
20 the derivative of hexahydroxycyclohexane has at least two sulphate groups.
4. The pharmaceutical composition of claim 1 wherein the hexahydroxycyclohexane is selected from the group
25 consisting of cis-inositol, epi-inositol, allo-inositol, neo-inositol, myo-inositol, muco-inositol, scyllo-inositol, L-(-)-chiro-inositol, and D-(+)-chiro-inositol.
- 30 5. The pharmaceutical composition of claim 1 wherein the hexahydroxycyclohexane is a derivative of myo-inositol.
6. The pharmaceutical composition of claim 5 wherein
35 the derivative of myo-inositol has at least two phosphate or sulfate groups.

7. The pharmaceutical composition of claim 6 wherein
5 the derivative of myo-inositol is inositol
hexaphosphate.

8. The pharmaceutical composition of claim 6 wherein
the derivative of myo-inositol is inositol hexasulphate.
10

9. The pharmaceutical composition of claim 1 wherein
the biologically active compound has at least one basic
nitrogen.

15 10. The pharmaceutical composition of claim 9 wherein
the basic nitrogen is selected from the group consisting
of amine, imine and ring nitrogen.

11. The pharmaceutical composition of claim 1 wherein
20 the biologically active compound is selected from the
group consisting of small molecules, macromolecules,
peptides, proteins, and enzymes.

12. The pharmaceutical composition of claim 1 wherein
25 the biologically active compound is selected from the
group consisting of doxorubicin, doxycyclin, diltiazam,
cyclobenzaprine, bacitracin, noscapine, erythromycin,
polymyxin, vancomycin, nortriptyline, quinidine,
ergotamine, benztropine, verapamil, flunarizine,
30 imipramine, gentamycin, kanamycin, neomycin,
amoxicillin, amikacin, arbekacin, bambermycins,
butirosin, dibekacin, dihydrostreptomycin, fortimicin,
isepamicin, micronimicin, netilmicin, paromycin,
ribostamycin, rapamycin, sisomicin, streptomycin and
35 tobramycin, amikacin, neomycin, streptomycin and
tobramycin, pyrimethamine, naltrexone, lidocaine,

5 prilocaine, mepivacaine, bupivacaine, tetracaine,
 ropivacaine, oxytocin, vasopressin, adrenocorticotrophic
 hormone (ACTH), epidermal growth factor (EGF), platelet-
 derived growth factor (PDGF), prolactin, luteinising
 hormone, luteinizing hormone releasing hormone (LHRH),
 10 LHRH agonists, LHRH antagonists, growth hormones
 (including human, porcine, and bovine), growth hormone
 releasing factor, insulin, erythropoietin (including all
 proteins with erythropoietic activity), somatostatin,
 glucagon, interleukin, interferon-.alpha., interferon-
 15 .beta., interferon-.gamma., gastrin, tetragastrin,
 pentagastrin, urogastrone, secretin, calcitonin,
 enkephalins, endorphins, angiotensins, thyrotropin
 releasing hormone (TRH), tumor necrosis factor (TNF),
 parathyroid hormone (PTH), nerve growth factor (NGF),
 20 granulocyte-colony stimulating factor (G-CSF),
 granulocyte macrophage-colony stimulating factor (GM-
 CSF), macrophage-colony stimulating factor (M-CSF),
 heparinase, vascular endothelial growth factor (VEGF),
 bone morphogenic protein (BMP), hANP, glucagon-like
 25 peptide (GLP-1), exenatide, peptide YY (PYY), renin,
 bradykinin, bacitracins, polymyxins, colistins,
 tyrocidine, gramicidins, cyclosporins (which includes
 synthetic analogues and pharmacologically active
 fragments thereof), enzymes, cytokines, antibodies,
 30 vaccines, antibiotics, antibodies, glycoproteins,
 follicle stimulating hormone, kyotorphin, taftsin,
 thymopoietin, thymosin, thymostimulin, thymic humoral
 factor, serum thymic factor, colony stimulating factors,
 motilin, bombesin, dinorphin, neurotensin, cerulein,
 35 urokinase, kallikrein, substance P analogues and
 antagonists, angiotensin II, blood coagulation factor

- 5 VII and IX, lysozyme, gramicidines, melanocyte
stimulating hormone, thyroid hormone releasing hormone,
thyroid stimulating hormone, pancreozymin,
cholecystokinin, human placental lactogen, human
chorionic gonadotrophin, protein synthesis stimulating
10 peptide, gastric inhibitory peptide, vasoactive
intestinal peptide, platelet derived growth factor, and
synthetic analogues and modifications and
pharmacologically-active fragments thereof.
- 15 13. The pharmaceutical composition of claim 11 wherein
the biologically active compound is selected from the
group consisting of doxorubicin, rapamycin, naltrexone,
epidermal growth factor (EGF), LHRH agonists, LHRH
antagonists, growth hormones, growth hormone releasing
20 factor, octreotide, interferon-alpha, interferon-beta,
interferon-gamma, calcitonin, parathyroid hormone (PTH),
glucagon-like peptide (GLP-1), peptide YY (PYY), and
synthetic analogues and modifications and
pharmacologically-active fragments thereof.
- 25 14. The pharmaceutical composition of claim 1 wherein
the biologically active compound is doxorubicin.
15. The pharmaceutical composition of claim 1 wherein
30 the biologically active compound is glycagon like
peptide 1 (GLP-1) and its analogues.
16. The pharmaceutical composition of claim 1 wherein
the biologically active compound is Octreotide.
- 35 17. The pharmaceutical composition of claim 1 wherein

5 the biologically active compound is peptide YY (PYY).

18. The pharmaceutical composition of claim 1 wherein
the biodegradable, water insoluble polymer is selected
10 from the group consisting of polylactides,
polyglycolides, poly(lactide-co- glycolide)s,
polycaprolactones, polydioxanones, polycarbonates,
polyhydroxybutyrates, polyalkylene oxalates,
polyanhydrides, polyamides, polyesteramides,
15 polyurethanes, polyacetals, polyorthocarbonates,
Polyphosphazenes, polyhydroxyvalerates, polyalkylene
succinates, polyorthoesters, and copolymers, block
copolymers, branched copolymers, terpolymers and
combinations and mixtures thereof.

20

19. The pharmaceutical composition of claim 1 wherein
the pharmaceutically acceptable carrier comprises an
environment responsive polymer or gel.

25

20. The pharmaceutical composition of claim 19 wherein
the environment responsive polymer or gel is
thermosensitive, pH sensitive, or electrically
sensitive.

30

21. The pharmaceutical composition of claim 1 in the
form selected from the group consisting of injectable
solutions or suspensions, particles, films,
pellets, cylinders, discs, microcapsules, microspheres,
35 nanospheres, microparticles, wafers, micelles, and
liposomes.

22. A pharmaceutical composition comprising:

5 a) a complex of a biologically active compound
having at least one basic functional group and a
derivative of hexahydroxycyclohexane having at least two
negatively charged functional groups; and

 b) a pharmaceutically acceptable carrier comprising
10 a biodegradable, water-insoluble polymer,
for use in administering a biologically active compound to
warm-blooded animals for the sustained, controlled
release of the biologically active compound over a period of
time.

15

23. The use of the pharmaceutical composition of claim 22
wherein the pharmaceutical composition is administered by
oral administration, parenteral administration; mucosal
administration; ophthalmic administration; subcutaneous,
20 intraarticular or intramuscular injection; inhalation; or
topical administration.

24. A process for preparing a composition characterized
by sustained, controlled release of biologically active
25 compound(s), comprising: a) separately dissolving a
biologically active compound having at least one basic
functional group, and a derivative of
hexahydroxycyclohexane having at least two negatively
charged functional groups; and b) mixing the dissolved
30 biologically active compound and derivative of
hexahydroxycyclohexane to produce a complex.

25. The process of claim 24 further comprising the
step of dispersing the complex into a pharmaceutically
35 acceptable carrier comprising a biodegradable, water-
insoluble polymer.

5 26. The process of claim 25, wherein the complex is dispersed into the pharmaceutically acceptable carrier by dry-mixing, dissolution in an organic solvent, or melting.

10 27. A pharmaceutical composition comprising:

a) a complex of a biologically active compound having at least one basic functional group and a polyanion derived from hexahydroxycyclohexane having at least two negatively charged functional groups;

15 b) a biodegradable, water-insoluble polymer; and

c) a pharmaceutically acceptable water miscible or dispersible organic solvent.

28. The composition of claim 27 wherein the
20 pharmaceutically acceptable organic solvent is selected from a group of N-methyl-2-pyrrolidone, N, N-dimethylformamide, dimethyl sulfoxide, propylene carbonate, caprolactam, glycofural, di(propylene glycol) methyl ether, di(propylene glycol) dimethyl ether, di(propylene glycol) methyl ether
25 acetate, methoxypolyethylene glycol 350, alkoypolyethylene glycol, polyethylene glycol esters, triacetin, benzyl benzoate, benzyl alcohol, ethyl lactate, glyceryl triacetate, esters of citric acid, polyethylene, glycols, and combination thereof.